Patients at risk of recidivism: emerging concerns regarding a reform of long-term illnesses
As the French healthcare system faces a growing financial imbalance, a major reform concerning long-term illnesses (ALD) raises major concerns. In 2025, the French health insurance proposes to review the status of patients suffering from chronic conditions, notably through the suspension of the ALD scheme for those considered to be in remission or cured. This measure, intended to reduce an estimated deficit of 16 billion euros this year, but forecast to rise to 41 billion by 2035, highlights a major issue: how to maintain optimal care without excluding patients at risk of recurrence? Faced with the possibility of early exit from the 100% reimbursed scheme, the medical community expresses skepticism, recalling the complexity of chronic illnesses and often prolonged after-effects, including disabling sequelae. Furthermore, the reform also plans the creation of a new “chronic risk” status, with tailored and graded management. In this environment, pharmaceutical laboratories such as Sanofi, Roche, or Novartis remain key players in research and treatment, operating in a rapidly changing landscape.
The debate is enrichened by questions about the very definition of “complete remission” and about the necessary continuity of care, including psychological support, for post-treatment patients. This questioning resonates particularly in pathologies with a high risk of relapse, such as cancers, where patients may present heavy sequelae and persistent anxiety about possible recurrence. The measure, which is only beginning to take shape, could permanently alter LES management of ALD in France, raising calls for vigilance and adaptation of support systems.
Financial and structural challenges of the reform of long-term illnesses
The proposed reform of the health insurance highlights a significant economic challenge. Today, long-term illnesses account for nearly 20% of the French population, approximately 13.7 million people, but already concentrate two-thirds of the annual expenses of the Primary Health Insurance Fund (CPAM). This economic burden is scrutinized as the overall deficit of the health insurance exceeds 16 billion euros for the current year, with projections indicating an increase potentially reaching 41 billion euros by 2035, posing a significant risk of budget overruns if no corrective measures are taken.
The government project, supported notably by Yannick Neuder, Minister of Health, involves suspending the ALD status for patients considered to be in complete remission, in order to reduce full coverage of care within this framework. This suspension would be implemented through a graded reimbursement system, no longer guaranteeing the full 100% of medical expenses related to the pathology once the acute phase is over. The goal set by the health insurance is thus to control expenditures while trying to prevent systematic exclusion of patients in case of recurrence or late complications.
Another important aspect of the reform aims to defer entrance into the ALD scheme by introducing an intermediate status called “chronic risk.” This measure would aim to lighten the initial coverage for those with a pathology requiring monitoring but not immediately justifying full reimbursement, while guaranteeing access to a specific list of reimbursable and enforceable care at 100% for each long-term condition.
- 🌐 A major economic challenge: growing deficit and impact on the CPAM
- 📉 Targeted reduction of coverage for patients in remission or cured
- ⏳ Delaying the activation of the ALD scheme through a new specific status
- ⚠️ Maintaining access to the scheme in case of relapse or complications
| Indicator 📊 | Current value | Projection 2035 |
|---|---|---|
| Health insurance deficit | 16 billion € | 41 billion € |
| ALD population | 13.7 million (20% of population) | Estimated increase |
| Share of CPAM expenses dedicated to ALD | 2/3 | 3/4 |
Impact on care: what would change with the end of the ALD status in case of remission
The ALD status currently guarantees full reimbursement at 100% by social security for care related to serious or chronic conditions. This comprehensive coverage, renewed every five years, allows patients to benefit from substantial financial support, especially important for heavy pathologies like cancer, diabetes, or Alzheimer’s disease. The proposal to eliminate the ALD status once the patient is considered in complete remission disrupts this traditional mechanism.
Under this hypothesis, the patient would no longer automatically benefit from 100% coverage for their pathology, exposing them to additional costs, especially in areas where fee overruns are common—a point already highlighted by many practitioners. However, the scheme theoretically allows re-entering the ALD scheme in case of relapse or late-occurring sequelae, but the speed and ease of such re-entry are debated.
Moreover, suspending the ALD status would affect patients for whom medical surveillance remains essential, notably in oncology, where hormonal treatments or prolonged follow-ups are integral parts of the care pathway. A concrete example: for breast cancer, hormone therapy can last a minimum of five years, highlighting the arbitrariness around the notion of “complete remission.”
- 💊 Reduced access to 100% reimbursements related to care
- 💸 Increased risk of patient costs (fee overruns, deductibles)
- 📅 Need for diligent medical follow-up, even during remission
- 🔄 Possibility of returning to the ALD scheme in case of recurrence, but ongoing uncertainties
| Aspects covered | Current ALD situation | After reform (in remission) |
|---|---|---|
| Medical care reimbursement | 100% Social Security | Variable, probably partial |
| Post-treatment follow-up | Ease and full support | Multiple consultations could be counted outside ALD |
| Medication management | Complete according to pathology | Risk of differentiated coverage |
| Psychological support | Recommended and accessible | Less protected, criticized by professionals |
This reform, aimed at easing the financial pressure on the system, raises significant concerns about premature exit from the scheme, particularly due to psychological and anxious issues related to fear of recurrence. The Gustave-Roussy center highlights that nearly 63.5% of cancer survivors still have heavy sequelae affecting their quality of life in the long term, raising questions about the relevance of suspending the ALD status in such conditions (source).
Medical professionals’ perspective: between caution and skepticism
Faced with reform proposals, practitioners and specialists in chronic diseases call for increased vigilance. They emphasize that, even under ALD status, patients often have to pay additional charges not covered, such as fee overruns or certain deductibles. Eliminating the scheme in case of “remission” would exacerbate these financial difficulties for patients whose health remains fragile.
For example, Catherine Simonin, representative of the League Against Cancer, tempers the idea: “In some cases, such as after surgical intervention without additional treatment, suspending ALD could be considered. But this remains very situation-dependent.”
Meanwhile, Professor Olivier Cussenot, from the National Association of Prostate Cancer Patients, recalls that the definition of “complete remission” remains a theoretical and arbitrary concept. Indeed, some patients can relapse after several decades. This uncertainty leads specialists to criticize an overly strict schedule for suspending the ALD status.
- 👨⚕️ Risk of worsening inequalities in healthcare access
- ⚠️ Difficulty in defining remission as a sole criterion
- 🕰 Importance of sustained medical and psychological follow-up
- 🔎 Call for a finer gradation rather than a sharp cutoff
| Medical arguments | Details |
|---|---|
| Fee overruns | Present even under ALD, likely to increase |
| Possible relapse after 20 years | Example: prostate cancer |
| Heavy sequelae post-cancer | 63.5% of patients retain sequelae |
| Necessary psychological follow-up | Crucial for anxious patients |
The risks of premature exit from the ALD scheme for patients at risk of relapse
Early exit from the ALD scheme raises several medical and social risks. For pathologies characterized by a strong tendency to relapse or complications, abrupt cessation of comprehensive management can lead to breaks in the care pathway. These disruptions are likely to cause health deteriorations, more frequent emergency visits, and even a general decline in quality of life.
Post-cancer issues, both physical and psychological, are a clear example of these challenges. Persistent fear of recurrence, alongside chronic pain or functional disorders, makes continuous monitoring and tailored support essential. However, the new scheme could limit this continuity.
- ⚕️ Increased risk of unmonitored complications
- 🔄 Difficulty in re-entering the scheme in case of relapse
- 🧠 Disruption of psychological support
- 🏥 Risk of increased hospital service use
| Possible consequences | Impacts |
|---|---|
| Breakdown in medical follow-up | Possible decline in health status |
| Losing 100% coverage | Financial burdens increase |
| Increased anxiety | Prevents regular psychological support |
| Rise in emergency visits | Additional costs for the health insurance |
Experts insist on the need to anticipate these risks and to establish a dynamic and individualized follow-up, capable of adapting to patient evolutions. This approach resembles proven models such as the R-B-R (Risk-Need-Receptivity) model, used in some international prevention schemes to target the most vulnerable patients (source).
The role of pharmaceutical laboratories in the evolution of chronic disease treatments
In a context of reform and budget tensions, major pharmaceutical laboratories are key players, including Sanofi, Servier, Ipsen, Roche, Bayer, Novartis, Amgen, Merck, GSK, and Pfizer. Their role extends beyond drug supply to innovative patient support, development of targeted therapies, and collaboration with health authorities to optimize management.
Recent pharmaceutical advances in cancer treatment, cardiovascular diseases, and diabetes align with this dynamic. For example, hormone therapy for breast cancer, supported by laboratories like Novartis or Roche, illustrates the importance of prolonged follow-up, which cannot be compromised by early termination of the ALD scheme.
- 🔬 Research and therapeutic innovation for chronic diseases
- 🤝 Collaboration with public health actors
- 🌍 Development of personalized care protocols
- 💊 Offering long-term treatments essential to remission
| Laboratory 🏢 | Intervention areas | Examples of treatments |
|---|---|---|
| Sanofi | Diabetes, cardiovascular diseases | Insulin injections, monoclonal antibodies |
| Roche | Oncology, hematology | Hormone therapies, immunotherapies |
| Novartis | Cancer, autoimmune diseases | Targeted therapies, oral treatments |
| Pfizer | Oncology, inflammation | Tyrosine kinase inhibitors |
Perspectives on support systems and psychological management
Another crucial aspect concerns the psychological follow-up of ALD patients, especially those with a high risk of recurrence, such as post-cancer patients. The fear of recurrence, often underestimated, induces chronic stress and anxious vigilance, requiring tailored and often prolonged care.
The reform poses a major risk of weakening this psychological support by reducing the automatic recognition of 100% coverage. Yet, testimonials from professionals like René Ducroux, president of Atoutcancer, recall that this support is essential to maintain quality of life and prevent serious psychological decompensations.
- 🧠 Importance of regular psychological follow-up
- 👥 Prevention of anxiety related to recurrence fears
- 🔄 Need for integrated care between somatic and psychological treatments
- 📈 Risk of overall health deterioration without support
| Care element | Current situation | Post-reform risk |
|---|---|---|
| Access to psychological follow-up | Encouraged and often covered | Less systematic, risk of disruption |
| Support for quality of life | Maintained through ALD schemes | Increased fragility |
| Post-treatment follow-up | Continuous and individualized | Possible interruption |
| Prevention of psychic relapses | Prioritized | Less well ensured |
International comparison: strategies and management of long-term illnesses
The issue of long-term illnesses and recurrence risk is not unique to France. Several European countries have experimented with various approaches to reconcile healthcare spending control and quality monitoring of chronic patients. In Germany, for example, setting up a hierarchical management system with adapted reimbursement tiers aims to handle these complex situations.
In the United Kingdom, the National Health Service (NHS) favors integrated monitoring between hospital sectors and primary care, with reinforced support around patients at high risk of relapse. These measures combine robust funding with close care coordination, while seeking to avoid disruptions.
- 🇩🇪 Germany: gradual adaptation of management approaches
- 🇬🇧 UK: integrated monitoring and care coordination
- 🇫🇷 France: partial suspension project, still under debate
- 🌐 Possible learning from foreign models
| Countries 🌍 | Main approach | Advantages | Disadvantages |
|---|---|---|---|
| Germany | Gradual reimbursement tiers | Cost control, flexibility | Administrative complexity |
| UK | Multidisciplinary integrated monitoring | Continuity of care, prevention | Resource strain on the system |
| France (project) | Partial suspension of ALD status | Potential cost reduction | Risk of excluding vulnerable patients |
FAQ – Frequently asked questions about the reform of long-term illnesses and recurrence risk
- ❓ What exactly is the ALD status?
The ALD status allows comprehensive coverage by social security for care related to a chronic or serious condition requiring prolonged treatment. - ❓ Why does health insurance want to reform this scheme?
Faced with a growing deficit, health insurance seeks to control costs by suspending the scheme for patients in complete remission, while retaining possibilities for re-entry. - ❓ What are the risks of premature exit from the ALD scheme?
An early exit can lead to gaps in medical follow-up, increased costs borne by the patient, and significant psychological weakening. - ❓ How do pharmaceutical laboratories participate in this evolution?
They develop innovative treatments, extend therapeutic possibilities, and collaborate with authorities to optimize management of long-term conditions. - ❓ Are there alternative models in other countries for managing these issues?
Countries like Germany and the UK have set up graduated or integrated systems that could serve as references to refine the French reform.
Source: www.letelegramme.fr
Entraîne-toi avec nos Quiz de révision
Fini les lectures passives. Pour retenir les notions clés du BTS Assurance, teste-toi ! Inscris-toi pour recevoir 1 quiz par jour directement dans ta boîte mail.
